These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 26761105)

  • 1. Comparison between Oncotype DX test and standard prognostic criteria in estrogen receptor positive early-stage breast cancer.
    Freitas MR; Simon SD
    Einstein (Sao Paulo); 2011 Sep; 9(3):354-8. PubMed ID: 26761105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
    Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
    Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
    Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
    Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates.
    Jaafar H; Bashir MA; Taher A; Qawasmeh K; Jaloudi M
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):354-60. PubMed ID: 25243360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients.
    Huang Z; Qin Q; Xia L; Lian B; Tan Q; Yu Y; Mo Q
    Cancer Manag Res; 2021; 13():587-593. PubMed ID: 33519238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer.
    Cotter MB; Dakin A; Maguire A; Walshe JM; Kennedy MJ; Dunne B; Riain CÓ; Quinn CM
    Virchows Arch; 2017 Sep; 471(3):321-328. PubMed ID: 28707056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
    D'Alfonso TM; van Laar RK; Vahdat LT; Hussain W; Flinchum R; Brown N; John LS; Shin SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):705-15. PubMed ID: 23774991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
    Park MM; Ebel JJ; Zhao W; Zynger DL
    Breast J; 2014; 20(1):37-45. PubMed ID: 24261318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menopausal status does not predict Oncotype DX recurrence score.
    Carr DN; Vera N; Sun W; Lee MC; Hoover S; Fulp W; Acs G; Laronga C
    J Surg Res; 2015 Sep; 198(1):27-33. PubMed ID: 26095420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the role of pharmacy technicians in reviewing the eligibility for Oncotype DX genomic test and the impact of the test on treatment plans in breast cancer patients.
    Cheng V; Markarian A; de Lemos ML; Schaff K
    J Oncol Pharm Pract; 2019 Jul; 25(5):1167-1173. PubMed ID: 30348071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice.
    Gradishar WJ; Hansen NM; Susnik B
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-7. PubMed ID: 19536946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
    Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
    Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Yang M; Rajan S; Issa AM
    Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.
    Markopoulos C; Xepapadakis G; Venizelos V; Tsiftsoglou A; Misitzis J; Panoussis D; Antonopoulou Z; Stathoulopoulou M; Zobolas V; Gogas H
    Eur J Surg Oncol; 2012 May; 38(5):413-9. PubMed ID: 22425282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit.
    Kim J; Kim A; Kim C
    Oncol Lett; 2019 Feb; 17(2):1812-1818. PubMed ID: 30675242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score.
    Zhang M; Sadinski M; Haddad D; Bae MS; Martinez D; Morris EA; Gibbs P; Sutton EJ
    Front Oncol; 2020; 10():595820. PubMed ID: 33614481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.
    Markopoulos C
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):179-94. PubMed ID: 23406559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.